Literature DB >> 21981662

Fatal transfusion-associated graft-versus-host disease with concomitant immune hemolysis in a group A combat trauma patient resuscitated with group O fresh whole blood.

Colleen Gilstad1, Mark Roschewski, Justin Wells, Andrew Delmas, Jeffrey Lackey, Paul Uribe, Christian Popa, Timothy Jardeleza, Stuart Roop.   

Abstract

Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but well-established fatal complication of blood transfusion. It can occur in immunocompetent patients when they receive transfusions from human leukocyte antigen-haploidentical donors who have lymphocytes with antigens that are not recognized as foreign by the host, but that recognize the host's tissues as foreign. It is generally viewed as a T-cell-mediated process. Graft-induced immune hemolysis or passenger lymphocyte syndrome is a well-described complication of marrow or solid organ transplantation in which immune competent donor B cells produce alloantibodies to recipient red blood cell (RBC) antigens and cause hemolysis of the recipient's RBCs. It is generally considered as a separate process from GVHD, although it could be considered a type of GVHD. Despite the theoretical possibility of both a B-cell and T-cell component to TA-GVHD, detection of a humoral antibody in cases of acute TA-GVHD has not been described. We describe the clinical course and laboratory evaluation of a group A combat trauma patient who was acutely resuscitated with group O fresh whole blood and RBCs and group AB fresh-frozen plasma who experienced the onset of the clinical symptoms of TA-GVHD as well as the onset of hemolysis due to donor-derived anti-A in his plasma 11 days after transfusion.
© 2011 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21981662     DOI: 10.1111/j.1537-2995.2011.03365.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

Review 1.  Fresh whole blood transfusion capability for Special Operations Forces.

Authors:  Andrew Beckett; Jeannie Callum; Luis Teodoro da Luz; Joanne Schmid; Christopher Funk; Elon Glassberg; Homer Tien
Journal:  Can J Surg       Date:  2015-06       Impact factor: 2.089

Review 2.  Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety.

Authors:  Paula H B Bolton-Maggs; Hannah Cohen
Journal:  Br J Haematol       Date:  2013-09-14       Impact factor: 6.998

3.  Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation.

Authors:  Steve Kleinman; Adonis Stassinopoulos
Journal:  Transfusion       Date:  2015-08-25       Impact factor: 3.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.